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The clinical evolution of the chronic form of Human African Trypanosomiasis starts with the 
haematolymphatic or first stage (P1). The meningoencephalitic or second stage (P2) begins when 
trypanosomes reach the cerebrospinal fluid (CSF). The classical stage determination method is based 
on CSF cell count, CSF protein concentration and/or the presence of trypanosomes detected in CSF. 
However their cut-off values and the sensitivity of detection of trypanosomes in CSF remains doubtful 
while the appropriate treatment depends on this determination of disease stage. Thus, the classical 
stage determination is reconsidered using new serological tests, and results were compared to the 
clinical data. Thirty-eight patients were classified into 4 clinical groups according to the observed 
degree of severity of neuropsychiatric signs. Based on multivariate analysis to evaluate the relevance of 
the new serological tests as compared with clinical groups, we confirm that Latex IgM CSF, cheap and 
easy to perform under field conditions, may improve stage determination of the disease. 
 
Key words: Human African Trypanosomiasis, stage determination, Latex IgM. 
 
 
INTRODUCTION 
 
The clinical evolution of the chronic form of Human 
African Trypanosomiasis (HAT) starts with the 
haematolymphatic or first stage (P1) with a few typical 
clinical signs (such as the primary lesion or trypanosomal 
chancre, or the posterior cervical swollen lymph node). 
The meningoencephalitic or second stage (P2) begins 
when trypanosomes reach the cerebrospinal fluid (CSF) 
with the progressive appearance of neurological 
disorders. The  classical  stage  determination  method  is  
 
 
 
 
*Corresponding author.  E-mail: truc@ird.fr. Tel: +33 611 888 
828. 
based on CSF cell count (cut-off, 5 cells/µl), CSF protein 
concentration (cut-off, 37 mg/100 ml by the dye-binding 
protein assay) and/or the presence of trypanosomes 
detected by simple or double centrifugation of CSF 
(WHO, 1998). However the cut-off values and the 
sensitivity of detection of trypanosomes in CSF remain 
doubtful (Truc et al., 1999). On the other hand, clinical 
examination for detection of neurological disorders may 
contribute to detect a second stage of the disease but is 
not satisfactory either (Bisser et al., 2000). However, the 
appropriate treatment requires an accurate determination 
of disease stage. Indeed, the treatment of patients in 
stage P1 is usually pentamidine, while melarsoprol is 
used  for  stage  P2.  Because   of   toxicity   and   severe,  
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potentially fatal side effects of melarsoprol and the 
possibility to cure some P2 patients using pentamidine 
(Doua et al., 1996), stage determination must be highly 
accurate. 
Recently, several new techniques for parasite detection 
in the CSF have been discovered. For example, these 
techniques include specific IgM antibodies (Lejon et al., 
1998, 2002 ; Büscher et al., 1999), anti-
galactocerebroside antibodies in CSF produced in 
response to the progressive demyelinating process 
triggered by the presence of trypanosomes in the cerebral 
environment (Bisser et al., 2000), or blood-cerebrospinal 
fluid barrier dysfunction and IgM detection (Bisser et al., 
2002).  
Thus the classical stage determination might be 
reconsidered using these new serological techniques, and 
results could be compared to clinical data. Indeed, 
patients could be classified into 4 clinical groups 
according to the observed clinical syndroms. Similar 
classification was already proposed (Bisser et al., 2000). 
Based on multivariate analysis to evaluate the relevance 
of the new serological tests as compared with clinical 
groups, we confirmed that the Latex IGM could improve 
stage determination. 
 
 
PATIENTS AND METHODS 
 
Patients, diagnostic and treatments 
 
The consenting patients were diagnosed between 1996 and 1998 in 
Côte d’Ivoire either at Daloa (Projet de Recherche sur la 
Trypanosomiase), Bouaflé (Regional Treatment Centre), or at 
various sites during several medical surveys conducted by the 
National Control Program against HAT and the HAT team from the 
Institut Pierre Richet located in Bouaké. 
Diagnosis was established according to the WHO protocol (WHO, 
1998), starting with a serological test using whole blood and plasma 
(Card Agglutination Test for Trypanosomiasis, CATT/T. T.b. 
gambiense; Magnus et al., 1978). In case of positive result, the 
search for trypanosomes was done either in lymphatic liquid by 
punction of swollen lymph node, or in whole blood by the mini-anion 
exchange centrifugation technique (mAECT; Lumsden et al., 1979). 
Stage determination was done by the classical method 
recommended by WHO (WHO, 1998): protein content dosage in 
CSF (P2 if > 37 mg/100 ml of CSF by the dye binding protein 
assay), the lymphocyte count in CSF (P2 if >5 cells/µl), and by 
microscopic examination of CSF after double centrifugation for 
direct observation of trypanosomes. One of these criteria with or 
without the presence of trypanosomes, forms the basis for second 
stage of HAT. 
 
 
Clinical examination 
  
Clinical examination included palpation (search for hepatomegaly, 
splenomegaly, lateral cervical lymphadenopathy), cardiovascular 
examination, dermatological examination (chancre of inoculation, 
trypanids), and search for endocrinological disorders (impotence, 
facial oedema, amenorrhoea, spontaneous abortion). The 
neurological disorders were mainly the alteration of mental state 
(psychiatric symptoms), abnormal reflexes, tone and co-ordination 
disorders, hyperaesthesia, sleep disturbances (alteration of 
circadian rythm), and the presence of archaic reflexes. 
Patients were asked about other clinical symptoms such as 
asthenia, anorexia, fever, headache, nausea and pruritus. Several 
questions were asked also to patients or their family in order to 
estimate roughly the mode of evolution of the disease. 
The presence or absence of each symptom, in particular these 
relevant to neurological disorders (Jamonneau et al., 2002), allowed 
the classification of patients into 4 groups, from group 0 
corresponding to the absence of neurological signs to group 3 
corresponding to the presence of a neurological syndrome. Groups 
1 and 2 correspond to intermediate clinical patterns with some 
neurological disorder noted for patients from the group 2. 
 
 
Laboratory examination  
 
For all tests, venous samples were obtained by venepuncture, and 
CSF by lumbar puncture before treatment. Serum and CSF were 
aliquoted (2 tubes of 1.5 ml for each fluid) and stored in liquid 
nitrogen. These tubes were shipped to the Institute of Tropical 
Medicine in Antwerp (Belgium), the Institute of Tropical Neurology in 
Limoges (France), and the Laboratory of Parasitology, University of 
Bordeaux II (France). The following dosages were performed: (1) 
Determination of the end titre (ET) using serum for CATT/T. b. 
gambiense (Magnus et al., 1978). The test is positive if ET>¼. (2) 
Determination of the end titre (ET) using serum for Latex/T. b. 
gambiense (Büscher et al., 1991). The test is positive if ET>1/16. (3) 
Determination of the end titre (ET) using CSF for Latex/T. b. 
gambiense (Büscher et al., 1999). The test is positive if ET>1. (4) 
Determination of the end titre (ET) using CSF for Latex/IgM. The 
test is positive if ET>1/16 (Lejon et al., 2002). (5) CSF protein 
concentration using the Kit BCA (Pierce). The cut off-value 
considered is 750 mg/l to determine a positive result. (6) Dosage of 
albumin concentration in serum and CSF by nephelometry (Lejon et 
al., 2002). The functionality of the blood-CSF barrier was evaluated 
using the CSF/serum albumin ratio, Qalb.  The age-related upper 
reference limits for Qalb are 5x10-3 (up to 15 years), 6.5x10-3 (up to 
40 years) and 8x10-3 (up to 60 years). If Qalb>7.4, it might indicate a 
blood-CSF barrier dysfunction. (7) Dosage of total IgM and IgG 
concentrations in serum and CSF by nephelometry (Bisser et al., 
1997; Lejon et al., 1998). (8) Dosage of specific IgM and IgG 
concentrations in serum and CSF by ELISA (Lejon et al., 1998) 
using antibodies against 3 specific antigenic variants LiTat 1.3, 1.5 
and 1.6. These dosages allow calculation of the Organism Specific 
Antibodies Index (OSAI), i.e. IgG OSAI and IgM OSAI. OSAI>1.5 
indicates an infection in the central nervous system (CNS; Reiber, 
1998). (9) Dosage of anti-cysteine, anti-NO-cysteine, anti-
tryptophan and anti-NO-tryptophan-like epitope antibodies in serum 
by ELISA (Boullerne et al., 1995). (10) Dosage of anti-
galactocerebroside antibodies (anti-GalC) in serum and CSF by 
ELISA (Amevidge et al., 1992). (11) Dosage of anti-neurofilament 
antibodies in serum and CSF by ELISA (Ayed et al., 1997). 
 
 
Statistical analysis  
 
First we used a discriminant analysis to assign actual group 
membership, i.e. the 4 clinical groups as defined above, against 
predicted membership (Wilkinson et al., 1992). To compute this 
multivariate model, we used all the available discriminators to 
predict the 4 groups, and then we selected as much as possible for 
optimal minimal models using stepwise discriminant analysis. For 
clarity, we only illustrate the optimal minimal model we obtained for 
predicting actual group membership. 
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Table 1. Relevant biological and clinical results for each patient. The results of other laboratory examinations performed (see 
Patients and Methods) were not statistically significant (p>0.05) between patients assigned to clinical groups. 
 
Patient no. Age Stage (WHO) Clinical group Cell/µl CSF Tryps CSF Protein CSF (mg/l) Latex IgM CSF (end titre) 
611 47 1 0 0 - 487 8 
612 11 1 0 0 - 653 2 
613 11 1 0 0 - 554 0 
614 13 1 0 0 - 507 1 
636 29 1 0 4 - 573 64 
660 63 1 0 0 - 486 0 
661 11 1 0 0 - 537 32 
662 21 1 0 0 - 924 64 
664 12 1 0 0 - 621 1 
669 17 1 0 2 - 650 4 
2597 56 1 0 4 - 706 2 
2600 47 1 0 4 - 583 1 
2604 22 1 0 0 - 522 2 
665 55 1 3 0 - 1218 128 
2561 14 2 0 28 - 594 8 
2584 45 2 0 6 - 665 8 
2598 35 2 0 6 - 627 0 
2601 56 2 0 10 - 761 4 
2603 38 2 0 12 - 514 4 
602 23 2 0 45 - 1063 128 
2569 48 2 0 304 + 1316 128 
2587 65 2 0 87 - 679 32 
2499 65 2 1 482 + 1332 128 
2570 14 2 1 848 + 974 128 
635 55 2 2 240 + 1198 128 
648 40 2 2 15 - 757 128 
2548 37 2 2 710 + 1179 64 
2557 30 2 2 1058 + 1546 128 
2582 41 2 2 6 + 774 16 
603 15 2 3 140 + 1302 128 
610 45 2 3 90 - 739 64 
634 31 2 3 48 + 1466 256 
638 9 2 3 113 + 776 128 
655 38 2 3 120 + 1828 128 
656 13 2 3 40 + 1474 256 
668 20 2 3 22 - 1358 128 
2562 29 2 3 888 + 1532 256 
2574 42 2 3 50 + 549 64 
 
 
 
Then a generalized linear model (GLIM) was built in order to 
assess simultaneously which explanatory variables and/or their 
interaction terms (2-way and 3-way interactions) better explained 
membership for the 4 clinical groups. Stepwise procedures were 
used to retain the best models as described in S-Plus 2000 guide to 
statistics  (Mathsoft, Inc. 1999).  When  the   order  of   entry  of   the  
 
different retained predictors altered residual deviances and partial 
testing, we decided to select variables according to their Akaike 
criterion (from the lowest to the highest; Crawley, 1993). For further 
details about statistical methods, see Mc Cullagh & J. A. Nelder. 
Generalized linear Models. Second edition, Chapman & Hall Ltd. 
London,  UK.   1989.   As   the   response   data   corresponded    to  
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Table 2. Summary of a Generalized Linear Model (GLIM) using a quasi-likelihood error structure (Phi=1.058) and a logit 
link function for explaining the 4 HAT clinical groups (see text) with the significant independent parameters retained after a 
stepwise selection procedure. Final model: Null deviance = 66.36, Residual deviance = 38.10, df = 2,36. 
 
P (Predictors) df Deviance Res. df Res. Dev. F-value 
Null   38 66.359  
Anti-GalC CSF O.D. 0.052774 1 4.2457 37 62.113 4.0112 
Latex IgM CSF E.T. 0.000031 1 24.0077 36 38.106 22.6817 
 
                    
 
proportions, we first used a Poisson error structure, and then we 
chose a Quasi-Likelihood estimation with a logit function since 
residuals tended to be overdispersed (McCullagh and Nelder, 
1989). In each case, predictive models based on classification were 
compared to explanatory models using GLIM. 
 
 
RESULTS AND DISCUSSION 
 
Thirty-eight patients were included in the present study. 
The results of laboratory examinations that are useful for 
stage determination according to WHO, and those of 
Latex IgM CSF which is the only one new highly 
significant variable for the new stage determination are 
summarised in Table 1. The best fit was obtained using a 
minimal model with lymphocytes/µl, protein in CSF, 
LatexIgM CSF, IgG OSAI and Qalb, to predict assignment 
to a given clinical group. According to the multivariate 
modeling, 18 patients were classified as group 0, and 2 
patients perfectly assigned to group 1. In addition, only 3 
patients of group 2 were predicted to belong to this group 
(60%), while 9 of those belonging to group 3 were 
correctly classified (90%). The classification score, on the 
average, was relatively high with 84% of patients correctly 
assigned to their relevant group of clinical symptoms. 
Results of GLIM to explain the classification of patients 
into the 4 clinical groups indicate that the only significant 
predictor variable was Latex IgM CSF (p=0.000031, Table 
2). This finding shows a strong influence of the Latex IgM 
CSF variable (85% of the total explained deviance) in 
categorizing the level of pathogenesis in patients affected 
by sleeping sickness.  
Out of the 3 classical tests recommended for stage 
determination by WHO (WHO, 1998), CSF protein 
concentration is not usually performed because of lack of 
reagent necessary for the traditional dye binding protein 
assay. In the present study, we used also a more 
sophisticated BCA technique (Pierce). However, routine 
use of new kit on a large scale in Africa appears to be 
unrealistic because of the specific and expensive devices 
and reagents required. Likewise, the low sensitivity of the 
search for trypanosomes in the CSF by the centrifugation 
technique is known as compared to PCR-based  methods  
used for parasite DNA detection (Truc et al., 1999). Once 
again and despite the improvement of its specificity (Truc 
et al., 2002), the use of PCR based methods for routine 
parasitological diagnosis appears unrealistic in the actual 
context in Africa.  
Some patients with trypanosomes in CSF were 
successfully cured using pentamidine in a previous study 
(Doua et al., 1996), probably because of a small amount 
of pentamidine passing through the blood-brain barrier 
(Van Nieuwenhove, 1999). The last classical test for 
stage determination is the CSF cells (or lymphocytes) 
count. The cut-off of 5 cells/µl is controversial (Bisser et 
al., 1997; Doua and Boa, 1994). In addition, even the 
conditions in which lumbar puncture is performed may 
influence final cell count. For example, bloody puncture 
and small volume of CSF may concentrate some cells 
originating from blood mixed together with CSF (when 
such a sample is not detectable by eye). Therefore, cell 
count takes into account all cells whatever their origin, 
leading to an overestimation of cells in CSF. In the 
absence of neurological disorders, the relevance of these 
3 classical tests remains important because it still leads to 
the decision of the appropriate treatment, pentamidine for 
P1 and melarsoprol for P2. The problem is not the 
reliability of these tests but their doubtful cut-off value and 
sensitivity. In the present study, statistical analysis 
confirmed the Latex IgM CSF as major parameter for the 
determination of CNS involvement (Lejon et al., 2002). 
This is an important improvement because Latex IgM 
CSF is a cheap and simple test, easy to perform under 
field conditions. However, the cut-off value is still 
controversial (Lejon et al., 2002). The interest of our 
integrated approach is to consider all clinical and 
biological results because it has been shown that the cut-
off value or sensitivity of only one technique is not 
sufficient to allow an accurate stage determination. The 
combination of several parameters appears to be more 
discriminant. Although the other biological markers were 
already described as specific of a CNS involvement and 
most of them are antibodies in serum (anti-cysteine, anti-
NO-cysteine, anti-tryptophan, anti-NO-tryptophan), our 
statistical analysis found also that the combination of only 
two parameters was much more relevant (Latex IgM CSF 
and anti-GalC CSF). It has been mentioned that routine 
use of a very sophisticated technique, such as O.D. 
determination for anti-GalC CSF under field conditions, 
appears unrealistic in the actual context of the control 
against HAT in Africa. Furthermore, the high correlation 
between IgM  and  anti-GalC  concentrations  in  the  CSF  
  
 
 
 
 
and the CNS involvement has already been demonstrated 
(Bisser et al., 2000). 
 Therefore, we recommend the use of Latex IgM CSF 
only after a large-scale evaluation (in particular to define 
an accurate cut-off value). The main advantage is its ease 
of use under field conditions and its rapidity. However, 
present results suggest that other biological markers still 
be of value especially when they can be analysed in 
serum. Indeed, this may avoid the lumbar puncture which 
is often a traumatism for the patient. Unfortunatly, lumbar 
puncture is still in use nowadays. 
In the absence of new drug for HAT treatment and 
because of the actual situation of sleeping sickness in 
Africa, it is crucial to reconsider the stage determination 
as soon as possible. Also, further investigations are 
required to avoid if possible lumbar puncture in the future. 
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